Once upon a prime: DCs shape cancer immunity
Trends in Cancer · 2023-02 · 9 (2) · 172-184
DOI: 10.1016/j.trecan.2022.10.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023-02. Verfasst von Maria Zagorulya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, MIT, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Takeda Pharmaceuticals U.S.A., Massachusetts Institute of Technology Ludwig Center for Molecular Oncology.
Abstract (Originalsprache)
Cytotoxic CD8+ T cells are potent killers of diseased cells, but their functional capacity is often compromised in cancer. The quality of antitumor T cell immunity is determined during T cell priming in the lymph node and further influenced by the local microenvironment of the tumor. Increasing evidence indicates that dendritic cells (DCs) have the capacity to precisely regulate the functional quality of antitumor T cell responses in both locations. In this review, we discuss recent advances in our understanding of how distinct DC-derived signals influence CD8+ T cell differentiation and antitumor functions. Insight into the mechanisms of DC-mediated regulation of antitumor immunity could inspire the development of improved approaches to prevent and reverse T cell dysfunction in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biology, MIT, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
- Department of Biology, MIT, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Ludwig Center at MIT's Koch Institute for Integrative Cancer Research, Cambridge, MA 0…
Förderung
- NCI NIH HHS
- Takeda Pharmaceuticals U.S.A.
- Massachusetts Institute of Technology Ludwig Center for Molecular Oncology
- Pew Charitable Trusts
- Massachusetts Institute of Technology Koch Institute for Integrative Cancer Research
- Merck
Zitieren
APA
Zagorulya, M., & Spranger, S. (2023). Once upon a prime: DCs shape cancer immunity. Trends in Cancer, 9(2), 172-184. https://doi.org/10.1016/j.trecan.2022.10.006
Vancouver
Zagorulya M, Spranger S. Once upon a prime: DCs shape cancer immunity. Trends in Cancer. 2023;9(2):172-184. doi:10.1016/j.trecan.2022.10.006
BibTeX
@article{Zagorulya2023,
author = {Zagorulya, Maria and Spranger, Stefani},
title = {Once upon a prime: DCs shape cancer immunity},
journal = {Trends in Cancer},
year = {2023},
volume = {9},
number = {2},
pages = {172--184},
doi = {10.1016/j.trecan.2022.10.006}
}
EUVIMED